Table 2. Clinical trials with reported results for neoadjuvant immunotherapy in NSCLC.
| Regimen | Study | Time | Phase | Sample size |
MPR (%) | pCR (%) | TRAEs (%) | |
|---|---|---|---|---|---|---|---|---|
| Any grade | Grade ≥3 | |||||||
| Nivolumab (22) (2 cycles) | NCT02259621 | 2018 | II | 20 | 45 | 15 | 23 | 4.5 |
| Sintilimab (23) (2 cycles) | NCT17013726 | 2020 | II | 37 | 40.5 | 16.2 | 52.5 | 10 |
| Atezolizumab (26) (2 cycles) | NCT02927301 (LCMC3) | 2021 | II | 147 | 20.4 | 6.8 | 56 | 5 |
| Atezolizumab (27) (1 cycle) | NCT02994576 (PRINCEPS) | 2020 | II | 29 | 14 | 0 | 3 | 0 |
| Pembrolizumab (28) (2 cycles) | NCT03197467 (NEOMUN) | 2020 | II | 15 | 27 | 13 | 53 | 33 |
| Durvalumab (29) (3 cycles) | NCT03030131 (IONESCO) | 2020 | II | 43 | 18.6 | 7 | – | – |
NSCLC, non-small cell lung cancer; MPR, major pathologic response; pCR, pathologic complete response; TRAE, treatment-related adverse event.